Huatai Financial Assists Innovent Biologics’s Listing on the HKEX Main Board

On Oct 31, 2018, Innovent Biologics (1801.HK ) was successfully listed on the main board of the Hong Kong Stock Exchange.

Huatai Financial was the Joint Global Coordinator, Joint Bookrunner, Joint Lead Manager of the deal. Huatai Financial demonstrated a strong sales and marketing capability and obtained huge recognition from the client by successfully locking up orders of c.USD500mn without arranging any roadshow meeting.